Biomarkers for neurodegenerative diseases

Area of Science:

• Neuroscience
• Biomarker Research
• Clinical Trials

Background:

• Improving early and presymptomatic detection of neurodegenerative diseases is a key research objective.
• Better tools are needed to assess disease progression in neurodegenerative disorders.
• Biomarkers are urgently required for upcoming clinical trials of potential disease-modifying therapies.

Purpose of the Study:

• To review the current landscape of biomarker research in major neurodegenerative diseases.
• To highlight the need for improved diagnostic and progression monitoring tools.

Main Methods:

• Review of various biomarker identification approaches.
• Discussion of imaging, neurophysiological, and cognitive testing.
• Inclusion of newer technologies: biochemical, proteomic, metabanomic, and gene array profiling of patient tissues and biofluids.

Main Results:

• Multiple approaches are being explored for biomarker discovery.
• Key recent findings across different technological areas are presented.
• The characteristics of an ideal biomarker are outlined, emphasizing reproducibility and relevance to disease progression.

Conclusions:

• No single biomarker is likely to meet all ideal characteristics for neurodegenerative diseases.
• A combination of biomarkers, including clinical assessments, imaging, and molecular profiling, will likely be required.
• Multimodal biomarker strategies are essential for accurate early diagnosis and effective evaluation of therapeutic interventions.